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ABSTRACT: Transcription factors are pivotal regulators of
gene transcription, and many diseases are associated with the
deregulation of transcriptional networks. In the heart, the
transcription factors GATA4 and NKX2-5 are required for
cardiogenesis. GATA4 and NKX2-5 interact physically, and
the activation of GATA4, in cooperation with NKX2-5, is
essential for stretch-induced cardiomyocyte hypertrophy.
Here, we report the identification of four small molecule
families that either inhibit or enhance the GATA4−NKX2-5
transcriptional synergy. A fragment-based screening, reporter
gene assay, and pharmacophore search were utilized for the
small molecule screening, identification, and optimization. The compounds modulated the hypertrophic agonist-induced cardiac
gene expression. The most potent hit compound, N-[4-(diethylamino)phenyl]-5-methyl-3-phenylisoxazole-4-carboxamide (3,
IC50 = 3 μM), exhibited no activity on the protein kinases involved in the regulation of GATA4 phosphorylation. The identified
and chemically and biologically characterized active compound, and its derivatives may provide a novel class of small molecules
for modulating heart regeneration.
■ INTRODUCTION
The regulation of gene expression depends on specific cis-
regulatory sequences that are located in gene promoter regions.
These DNA sequences are recognized by tissue-specific
transcription factors (TFs) in a sequence-specific manner,
and their combinatorial interactions underlie physiological
responses to developmental programs.1−3 In the heart,
developmental processes are controlled by an interplay
among the master cardiac TFs, such as GATA4, NKX2-5,
and TBX5.4−6 These TFs bind to the promoters/enhancers of
downstream targets as homo- or heteromultimeric complexes
to physically interact with and synergistically regulate their
target genes. GATA4 is one of the earliest-expressed TFs
during cardiac development, and its up-regulation is sufficient
to induce cardiogenesis in embryonic stem cells and promote a
cardiac cell fate in noncardiogenic cells.7 In the adult heart,
GATA4 is a critical regulator of cardiac regeneration8 and acts
as a key transcriptional controller of numerous cardiac genes,
including those encoding atrial natriuretic peptide (ANP),9 B-
type natriuretic peptide (BNP),10 α-myosin heavy chain (α-
MHC),11 and β-MHC.12 GATA4 binds to specific DNA
response elements with or without cofactors, e.g., NKX2-5,
TBX5, myocyte-specific enhancer factor 2 (MEF2), and serum
response factor (SRF).13 Mutational studies have shown that
the GATA consensus sites in combination with an NKX2-5
binding element are important for the mechanical stretch-
activated BNP transcription and sarcomere reorganization,14
thus implicating the GATA4−NKX2-5 interaction for the
response of cardiomyocytes to external stimuli, such as a
hemodynamic overload due to high blood pressure and
myocardial infarction.
GATA4 belongs to the GATA protein family (GATA1−6)
and is characterized by WGATAR-recognizing zinc-finger
domains that mediate DNA binding and protein−protein
interactions. Our previous work illustrated that the protein
assembly between GATA4 and NKX2-5, which is a critical
GATA4 cofactor, imposes a structural fold that is similar to that
of the evolutionally conserved DNA binding domains of
nuclear receptors.15 The significance of this particular protein−
protein complex has been further validated by the co-
occurrence of GATA4 and NKX2-5 in the binding site
locations.16 In addition to protein−protein interactions, the
function of GATA4 is modulated through post-translational
modifications. An increased GATA4 transcriptional activity has
been shown in luciferase reporter assays with phosphorylated,17
acetylated,18 or sumoylated GATA4 protein.19 Therefore, the
functional modulation of the GATA4 protein or the GATA4−
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NKX2-5 interaction could represent an innovative therapeutic
approach for cardiac regeneration20,21 or other pathophysio-
logical conditions.22 However, currently, there are no small
molecule inhibitors or activators of GATA4 function except for
one report describing inhibitors of GATA4 binding to DNA.23
Here, we utilized a fragment-based screening, reporter gene
assay based optimization, and pharmacophore search to identify
small molecules that modify the synergy between the
transcription factors GATA4 and NKX2-5 in vitro.
■ RESULTS
Primary Screening. Previously, we conducted a mutagenic
analysis of the second zinc finger domain to elucidate the
structural basis of the GATA4−NKX2-5 interaction.15 These
studies identified five highly conserved amino acids in the
second zinc finger (N272, R283, Q274, K299) and its C-
terminal extension (R319) that are critical for the physical and
functional interaction with the third α helix of the NKX2-5
homeodomain. An integration of the experimental data with
computational modeling suggested that the topology of the
GATA4−NKX2-5 interaction resembles that of nuclear
Figure 1. Cell-based reporter gene assay used for the screening of compound libraries targeting the GATA4−NKX2-5 transcriptional synergy. COS-
1 cells were transfected with the 3xNKE-luciferase reporter construct and GATA4 and NKX2-5 expression plasmids and treated with small molecules
for 24 h. The cells were lysed, and the luciferase reporter gene activity was measured by a luminometer. (A) Compounds 3−6 had a significant
inhibitory effect on the GATA4−NKX2-5 transcriptional synergy, while compound 7 enhanced the GATA4−NKX2-5 transcriptional synergy. (B)
Compound 3 dose-dependently inhibited the GATA4−NKX2-5 transcriptional synergy in the COS-1 cells. The data are shown as the mean ± SD, n
= 2−9: (∗∗) p < 0.01, (∗∗∗) p < 0.001 vs vehicle treatment.
Scheme 1. Overall Flowchart Illustrating the Process of Screening and Validating the GATA4−NKX2-5 Synergy Modulatorsa
aBNP, B-type natriuretic peptide; GPCR, G-protein-coupled receptor.
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Scheme 2. Chronological Workflow of the Hit Compound Search and Optimization Process Initiated from the Active
Fragmentsa
aScheme illustrates the molecular structure, compound code numbers, and corresponding IC50 values in the GATA4−NKX2-5 luciferase reporter
gene assay.
Table 1. Structural Variants of Hit Compound 3 in the Luciferase Reporter Gene Assay28
aKa is equal to the synergy activation.
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receptors.15 In agreement with those observations, GATA4 has
a synergistic effect with NKX2-5 on promoters that contain
multiple NKX2-5 high affinity response elements (NKEs).24,25
To evaluate the effect of the compounds on the functional
interaction between GATA4 and NKX2-5, we developed a
luciferase reporter gene assay specifically for the GATA4−
NKX2-5 transcriptional synergy.15 In this assay, mammalian
COS-1 cells were transfected with the protein expression
vectors pMT2-GATA4, pMT2-NKX2-5, both pMT2-GATA4
and pMT2-NKX2-5, or the empty control vector pMT2. The
transfection efficiencies of the vectors in the COS-1 cells were
verified by defining the protein levels of GATA4 and NKX2-5
by Western blotting.15 Typically, several limitations are
associated with the use of luciferase reporter assays.26 The
tested compounds may interfere with the luciferases and
decrease the assay signal, resulting in false positives. In addition,
the compounds may aggregate, have redox behavior, enzymati-
cally inhibit the reporter, or form complexes that interfere with
the fluorescence. Therefore, the positive findings obtained here
with the primary screening assay were further confirmed using
bioassays. As shown in Figure 1, the NKX2-5 protein activates
the construct containing three high affinity NKX2-5 binding
sites alone and synergistically with GATA4, while the GATA4
protein alone had only a negligible effect.
Initially, the compounds selected by the virtual screening for
the modulation of protein−protein interaction were tested
using an immunoprecipitation screening method, which
revealed 15 weak inhibitory compounds (Scheme 1). However,
the identified compounds were shown to be false positives in
the luciferase reporter assay and confirmatory bioassays, and
subsequently, this approach was discontinued.
An in silico analysis focusing on the DNA binding site in the
C-terminal zinc finger of GATA4 was carried out using a
collection of 39 randomly placed molecular fragments, followed
by energy minimization to reveal and rank the interaction
potentials of the fragments inside the implied binding cavity.
The compiled virtual assignments at the DNA binding site with
multiple copies of simultaneous chemical probes27 suggested a
pronounced electrostatic interaction among the rigid fragment
compounds with a negative charge/acceptor and aromatic
features. On the basis of these theoretical annotations, a cherry-
picked collection of 40 fragment compounds was purchased
and tested in vitro using the GATA4−NKX2-5 luciferase
reporter gene assay. These experiments identified two
compounds that inhibited the transcriptional synergy, i.e., 3,4-
diphenyl-1,2,5-oxadiazole (compound 1) and 2-perfluorophen-
yl-3-phenylacrylic acid (compound 2), at a concentration of 50
μM (Scheme 2).
Hit Optimization. A luciferase reporter gene assay based
optimization of the initial fragment compounds was achieved
by introducing sequential structural modifications and fragment
growth to uncover compounds with activity on the GATA4−
NKX2-5 transcriptional synergy. First, variable substituents
were inserted into the three-ring core of fragment 1. The
compounds with the para-substituted six-member ring were the
most effective. Second, different linkers with variable bond
lengths and chemical compositions were inserted between the
six- and five-member rings. The number of heavy atoms
between the aromatic rings of the compounds ranged from zero
to three. The most potent compound according to the
luciferase reporter gene assay, at a concentration of 10 μM,
was N-[4-(diethylamino)phenyl]-5-methyl-3-phenylisoxazole-
4-carboxamide (3) (Figure 1A), which dose-dependently
inhibited the GATA4−NKX2-5 transcriptional synergy (Figure
1B).28 A relatively rigid two heavy atom linker and the
hydrogen acceptor feature next to the five-member ring were
the essential structural features in successful fragment-to-hit
growth (Scheme 2). During the primary screening and hit
optimization, 800 small molecule entities were tested, including
at least 15 structurally related compounds in each of the three
active series to confirm the original findings and the structure−
activity relationships (Tables 1−3).
Pharmacophore Search. To further evaluate the active
molecular scaffold space, a pharmacophore model was built
based on the following three active compounds: 3, 4-[(4-
propoxybenzylidene)amino]-5-(pyridin-4-yl)-4H-1,2,4-triazole-
3-thiol (4), and isobutyl 4-(isonicotinamido)benzoate (5)
(Figure 2). All three active compounds have a relatively rigid
core structure, and therefore, the low energy conformations of
these compounds were used as a basis for the compound
superimposition and pharmacophore model. Subsequently, the
pharmacophore model was completed with excluding volumes
derived from the homology model of the GATA4-DNA binding
site. Furthermore, 15 inactive and structurally variable
compounds were selected from the parallel screening path
targeting the GATA4−NKX2-5 protein−protein interface.
Here, 14 of the 15 compounds screened was not detected by
the pharmacophore model. Finally, an in silico screening of the
commercial compound library was carried out using the
pharmacophore model. Consequently, 20 compounds were
purchased and tested in vitro using the luciferase reporter gene
assay, leading to the identification of a new active compound, 5-
(4-ethoxybenzylidene)-3-ethylthiazolidine-2,4-dione (6) at a
concentration of 5 μM, and its variants (Table 4).
All four compound families found during the in vitro
screening inhibited the GATA4−NKX2-5-induced synergistic
activation of the promoter containing the three high affinity
NKX2-5 binding sites. Interestingly, the reporter assay
screening also detected several weak hit compounds with the
potential to increase the GATA4−NKX2-5 transcriptional
synergy. These compounds have variable scaffolds but the
structural elements were similar to the structures that inhibited
the activation. Subsequently, during the small molecule
optimization of the inhibitory compound 3, surprisingly, we
detected a compound that strongly augmented the GATA4−
NKX2-5 synergy in the reporter gene assay (Figure 1A). The
structure of this activator compound, N-(4-chlorophenyl)-5-
methyl-N-(4-methyl-4,5-dihydrothiazol-2-yl)-3-phenylisoxa-
zole-4-carboxamide (7), partially overlaps the pharmacophore
model, which was developed based on inhibitory compounds
with an additional five-member ring moiety attached. Due to
the complexity of the compound structure, the synthesis of its
derivatives was not pursued in this study, and only one related
compound was tested to confirm this finding. Furthermore, the
screening of a small natural compound library identified the
flavonoids apigenin and luteolin as weak inhibitors of the
GATA4−NKX2-5 transcriptional synergy with IC50 values of
24 and 22 μM, respectively.
Aggregation of the Compounds. Aggregation of a
compound may result in artificial activity in luciferase enzyme
based assays.26 To evaluate the potential aggregation of the
compounds 3, 4, and 7, the testing conditions were mimicked,
and the light scattering of any particles/aggregates in the
mixture was measured using the nephelometric method.
Aggregation was only observed in the samples at a
concentration of 100 μM. At lower concentrations, the values
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were close to those observed in the blanks, indicating that there
is no detectable aggregation, except for compound 7, which
shows minor signs of aggregation at 30 μM (Figure S1 in
Supporting Information).
Chemical Stability of Compound 3. In addition, the
stability of compound 3 was studied for 5 and 10 days in mouse
embryonic stem cells (mESCs) in vitro at two different
concentrations (3 and 5 μM) with two blank treatments
(DMSO and embryoid body differentiation medium (EBDM))
added to the cell culture media. The intra- and extracellular
concentrations of compound 3 and metabolite 31 were
measured by HPLC/MS after performing specific sample
pretreatment and extraction procedures. The results demon-
strate that compound 3 is only modestly degraded during the
10 days in the cellular assay (Table S1). Furthermore, the
storage of compound 3 in DMSO at room temperature for 6
months did not result in degradation (data not shown).
Table 2. Structural Variants of Hit Compound 4 in the
Luciferase Reporter Gene Assay
Table 3. Structural Variants of Hit Compound 5 in the
Luciferase Reporter Gene Assay
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GATA4 Transcriptional Activity and GATA4−NKX2-5
Interaction. Compounds 3, 4, and 7 were evaluated in a
reporter assay in COS-1 cells by using BNP promoter reporter
constructs containing either the first 60 bp in the BNP
promoter including the proximal TATA-box (BNP minimal
promoter) (Figure S2A) or the first 90 bp that include also the
tandem GATA-site (Figure S2B). TATA-box in BNP promoter
acts as a functional GATA4 binding site.13 Compound 3
significantly inhibited GATA4 driven transactivation of
luciferase reporter constructs containing either BNP minimal
promoter (Figure S2A) or BNP promoter containing minimal
promoter and tandem GATA-site on −90 bp (Figure S2B).
Compound 4 showed similar tendency, yet a statistically
significant inhibition of gene transactivation was seen only with
construct containing both minimal promoter and tandem
GATA-sites (Figure S2B). Overall, the effects of all compounds
parallel those of primary screening assay with promoter
containing the three high affinity NKX2-5 binding sites and
are in agreement with the compound’s hypothetical mechanism
of action. In addition, we used an immunoprecipitation assay to
characterize further GATA4−NKX2-5 interaction. GATA4 and
NKX2-5 FLAG protein lysates were produced in COS-1 cells,
and FLAG-antibody bind agarose beads were used to pull down
NKX2-5 together with interacting GATA4. As shown in Figure
S3, compound 3 modestly decreased the intensity of GATA4−
NKX2-5 interaction, although this change was not statistically
significant (Figure S3).
GATA4 and NKX2-5 DNA Binding. Previously, El-
Hachem and Nemer have identified molecules that prevent
GATA4 activity by inhibiting its interaction with DNA and
blocking the activation of the downstream target genes of
GATA4.23 These effects were reported to be due to a decreased
GATA4-DNA interaction as evaluated by an electrophoretic
mobility shift assay (EMSA). To determine whether the active
compounds identified in the present study influence GATA4 or
NKX2-5 DNA binding, we performed EMSA using nuclear
proteins from both COS-1 cells and neonatal rat cardiomyo-
cytes. The compounds were incubated with the COS-1 nuclear
proteins, and then a 32P-labeled oligonucleotide targeting
GATA4 or NKX2-5 was added. Compound 3 did not alter the
GATA4 or NKX2-5 DNA binding. Compounds 4 and 5 had a
minor inhibitory effect on the NKX2-5 and GATA4 DNA
binding, respectively; however, these changes were not
statistically significant (Figure 3A and Figure 3B). Moreover,
neonatal rat cardiomyocytes were treated with the compounds
for 24 h, the nuclear proteins were extracted, and EMSA was
performed. In the cardiomyocytes, compound 3 inhibited the
GATA4 DNA binding by 29%, and compound 4 inhibited the
GATA4 DNA binding by 37% and the NKX2-5 DNA binding
by 29% (Figure 3C and Figure 3D). However, these changes
were not statistically significant, suggesting that the effects of
the small molecules on the GATA4- and NKX2-5-driven
transcriptional synergy are not due to the inhibition or
activation of the GATA4 or NKX2-5 DNA binding.
Biological Activity. The role of GATA4 in the heart ranges
from the differentiation, survival, and proliferation of cardiac
progenitors to the adaptive stress response, angiogenesis, and
myocardial repair of the postnatal heart.14 These diverse
GATA4 functions are thought to involve differential
interactions with cell-specific and signal-inducible cofactors.
GATA4 and NKX2-5 are critical transcription factors that
cooperatively regulate the mechanical stretch-responsive genes
ANP29 and BNP.30 Both ANP and BNP are expressed in the
developing and adult heart, and their gene expression is
markedly up-regulated in response to myocyte hypertrophy and
Figure 2. (A) C-terminal zinc finger of GATA4 mediates the DNA
binding and GATA4−NKX2-5 protein−protein interaction. Computa-
tional methods were applied to analyze and screen two separate
binding sites. A pharmacophore model with excluded volumes was
built for the DNA binding cavity of GATA4. (B) The low energy
conformations of compounds 3, 4, and 5 were utilized as a basis for the
pharmacophore model. All three compounds inhibited the GATA4−
NKX2-5 synergy in the luciferase reporter gene assay. Atom colors are
the following: white = hydrogen, gray = carbon, red = oxygen, blue =
nitrogen, and yellow = sulfur. Pharmacophore features are the
following: blue sphere = acceptor, orange sphere = aromatic, and
green sphere = hydrophobic.
Table 4. Structural Variants of Hit Compound 6 in the
Luciferase Reporter Gene Assay
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hemodynamic overload due to myocardial infarction and heart
failure.31,32 Therefore, we tested whether our newly discovered
active compounds could influence ANP and BNP gene
expression in vitro. Neonatal rat ventricular myocytes were
treated with endothelin-1 (ET-1), which is a well-established
hypertrophic agonist that activates the gene expression of both
ANP and BNP,33 and the compounds were added to the cells 1
h prior to ET-1. The compounds either augmented or inhibited
the ET-1-induced gene expression of ANP and BNP (Figure 4).
Consistently with the luciferase reporter gene assay finding in
which compound 3 inhibited the GATA4 and NKX2-5
transcriptional synergy, compound 3 also inhibited the ET-1-
stimulated BNP gene expression (68%, p < 0.05). There was
also a tendency for compound 3 to decrease the basal mRNA
levels of ANP (81%) and BNP (75%), and ET-1 stimulated the
gene expression of ANP (32%), but these changes were not
statistically significant (Figure 4A and Figure 4B). Compounds
8, 9, 10, and 62 inhibited the ET-1-induced increase in the
mRNA levels of ANP, and compound 8 also inhibited the
mRNA levels of BNP (Figure 4A and Figure 4B). In contrast,
compound 7, which is an activator of the GATA4−NKX2-5
transcriptional synergy, enhanced the baseline mRNA levels of
ANP (4.6-fold, p < 0.001) and BNP (6.4-fold, p < 0.001) and
ET-1-stimulated gene expression of BNP (2.1-fold, p < 0.001)
in the cardiomyocytes (Figure 4A,B). Finally, compound 4 had
a mixed action, acting as an inhibitor in the transcriptional
synergy assay but enhancing the basal ANP (8.6-fold, p <
0.001) and BNP (4.9-fold, p < 0.001) gene expression levels in
cardiomyocytes (Figure 4A,B).
The activity of the most potent compound, i.e., compound 3,
was further validated in a cardiomyocyte hypertrophy model by
utilizing cyclical stretching of ventricular myocytes. By use of
this experimental model, the co-operation of GATA4 and
NKX2-5 has been reported to be essential for mediating the
stretch response via the NKE.14 Myocytes were exposed to the
compound at a concentration of 10 μM, and after 48 h of
mechanical stretching, the myocyte area was measured. As
shown in Figure 4E, compound 3 significantly inhibited the
increase in the area of the myocytes in response to the
stretching, indicating that the compound inhibits hypertrophic
growth. Overall, the results show that the compounds can
modulate the hypertrophic response in myocytes in vitro, which
is consistent with the inhibition or activation of the GATA4−
NKX2-5 interaction (Figures 1 and 4).
Cytotoxicity. The cytotoxicity of the selected biologically
active compounds was evaluated by determining necrotic and
Figure 3. Effect of compounds on GATA4 and NKX2-5 protein DNA binding. (A, B) Nuclear proteins from COS-1 cells were extracted, and
binding reactions and EMSA were performed as described in the Experimental Section. The concentration of the compounds 3−5 was 50 μM. (C,
D) Neonatal rat cardiomyocytes were treated with the compounds 3, 4, and 7 for 24 h. Nuclear proteins were extracted, and binding reactions and
EMSA were performed as described in the Experimental Section. Specific GATA4 and NKX2-5 bands are indicated. The concentration of the
compounds was 50 μM. Supershift reactions were performed by incubating the reaction mixtures with anti-GATA4 and anti-NKX2-5 antibodies.
Asterisks denote the lanes with the supershifted samples. The dashed line indicates where the EMSA image has been cut. The data are shown relative
to the vehicle treatment as the mean ± SD, n = 3−5.
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apoptotic cell death by analyzing the release of adenylate kinase
(AK) and TUNEL-positive cells, respectively, in neonatal rat
cardiomyocytes. The cells were treated with each compound at
a concentration of 50 μM for 24 h. Compounds 3, 4, and 7
alone or together with ET-1 did not affect necrotic
cardiomyocyte death (Figure 5A). Compounds 3, 4, and 7
had no effect on apoptotic cell death (Figure 5B).
Protein Kinase Profiling. To characterize the effect of the
active compounds on the protein kinases, Cerep ExpresS
Diversity kinase profiling was performed. Of the 48 kinases
analyzed, compound 3, at a concentration of 30 μM, inhibited
Figure 4. Effect of different compounds in the bioassays. (A−D) Neonatal rat cardiomyocytes (CMs) were treated with 100 nM endothelin-1 (ET-
1) for 23 h. Compounds were added to the cells at concentrations of 10−100 μM 1 h prior to ET-1. The results are expressed as the ratio of ANP
and BNP mRNA to ribosomal 18 S RNA, which were all determined by RT-PCR at 24 h. The data are shown relative to the vehicle sample as the
mean ± SD: vehicle, n = 24; compounds, n = 3−6. (E) The effect of compound 3 on the hypertrophic response was investigated by exposing the
CMs to 10 μM for 48 h with or without stretching. After the stretching, the CMs were fixed, stained for cardiac α-actinin, F-actin, and nuclei, and
imaged under a fluorescence microscope. The surface area of the α-actinin expressing cells was determined from the images using CellProfiler
software. The results are expressed as the mean of three independent experiments ± SEM: (∗) p < 0.05, (∗∗) p < 0.01, (∗∗∗) p < 0.001 vs vehicle
treatment (A−D) or appropriate group (E).
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epidermal growth factor receptor kinase (EGFR) by 54% and
vascular endothelial growth factor receptor 2 kinase/kinase
insert domain receptor (VEGFR2/KDR) by 64% (Table S2).
In addition, compound 4 inhibited fibroblast growth factor
receptor 3 kinase (FGFR3) by 55% (Table S3). It is
noteworthy that compound 3 was inactive against p38α
mitogen-activated protein kinase (MAPK), glycogen synthase
kinase-3β (GSK-3β), extracellular signal-regulated kinase 2
(ERK2), protein kinase A (PKA), and Rho kinase 1 (ROCK1),
which all have been reported to be involved in the regulation of
GATA4 phosphorylation (Table S2).13
Cell-Based G-Protein Coupled Receptor Profiling. To
test the effect of the biologically active compound 3 on 165
different G-protein-coupled receptors (GPCRs), we used
Millipore GPCR profiler, which monitors calcium flux in cells
expressing specific GPCR and promiscuous GPCR-coupling
Gα15/16 proteins. Compound 3 inhibited cannabinoid receptor
type 2 (CB2), parathyroid hormone 2 receptor (PTH2), and
niacin receptor 1/G-protein-coupled receptor 109A
(GPR109A) with mean percentage inhibition values of 91.8,
59.5, and 58.5, respectively, but no significant agonistic effect
was found (Table S4). In addition, the previously reported
noncardiac inhibitory effect on ghrelin receptor was identified
in this study (65.2%).34
Molecular Modeling. A computational analysis based on a
model of GATA4−NKX2-5 bound to DNA suggests that the
structural arrangement of the C-terminal extension in the
second zinc finger of GATA4 plays a critical role in the
transcription factor networking in the cardiac context.35 The
functional preference of GATA4 is dependent on a distinct
trade-off between DNA binding and interacting with NKX2-5.
Both structural arrangements are dependent on and amplified
by post-translational modifications, such as phosphorylation
and acetylation.36 The evaluation of the protein structure
indicates that the DNA binding of a single GATA4 partially
depends on the extensive contact between the DNA and the C-
terminal extension in the second zinc finger. However, our
proposed GATA4−NKX2-5 interaction requires a dislocation
of the loop extension, resulting in an inability of GATA4 to
drive the synergy through the GATA binding site (Figure 6).
■ DISCUSSION AND CONCLUSIONS
Transcription factors are the fundamental regulators of gene
transcription, and many diseases, such as cancer, neuro-
degenerative disorders, and heart disease, are associated with
the deregulation of transcriptional networks.37 The under-
standing of these complex networks and pharmacological
strategies that modulate the activity of distinct transcription
factors will, therefore, be essential for the development of novel
therapeutic approaches. A proof for the relevance of directly
modulating transcription factors has been provided by targeting
nuclear receptors that contain a clearly defined ligand-binding
pocket and are activated by natural ligands, such as retinoic
acid, glucocorticoid, estrogen or androgen receptors. Moreover,
the design of small molecule drugs that interfere with
transcription factor/cofactor interactions or homo-/heterodi-
merization between cooperating transcription factor molecules
has yielded various drugs that are capable of counteracting
Figure 5. Cytotoxicity of compounds 3, 4, and 7 in neonatal rat
ventricular myocytes. (A) Adenylate kinase (AK) release was
determined after the cells were treated for 24 h with each compound
at a concentration of 50 μM. The data are shown relative to the vehicle
treatment as the mean ± SD, n = 3. (B) To detect apoptotic cells, a
TUNEL assay was performed as described in the Experimental
Section. TUNEL-positive cells were determined after the cells were
treated for 24 h with each compound at a concentration of 50 μM.
The data are shown as the mean ± SD, n = 2 (for compound 7 in
TUNEL assay, n = 1).
Figure 6. (A) C-terminal extension in the second zinc finger domain
(yellow ribbon) contributes to the DNA binding of GATA4. (B) For
the activation of the GATA4−NKX2-5 interaction, the loop extension
needs to relocate and (C) enforce the structural reorganization of the
GATA4 complex in the tandem GATA binding site. (C) The GATA4
and NKX2-5 proteins were overexpressed in the COS-1 cells. Nuclear
proteins were extracted, and EMSA was performed as described in the
Experimental Section. GATA4 alone (four parallel samples) or
together with NKX2-5 (four parallel samples) was incubated in
binding reactions with DNA. GATA4 binding to the rat BNP
promoter (−90 bp tandem GATA site) resulted in two separate bands,
and their intensities depended on the presence of NKX2-5.
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specific DNA-regulatory proteins.38 Thus, protein−protein
interactions of key transcription factors are likely to present
one of the next major classes of innovative therapeutic targets.
A substantial body of evidence suggests that a limited
number of regulatory transcription factors (e.g., GATA4,
HAND2, MEF2, NKX2-5, and TBX5) are needed for the
initiation of cardiac-like gene expression.20,39−41 Investigations
of heterotypical interactions involving GATA4 have revealed
that transcription factors that are critical for cardiac
reprogramming, such as MEF2,42 HAND2,43 and TBX5,44,45
tend to synergistically activate the GATA binding site (Scheme
3). In contrast, the overexpression of either NKX2-525 or SRF46
leads to protein complex formation and, consequently, the
activation of their corresponding sites with a diminished ability
to drive cardiac transdifferentiation.47 In addition to the
GATA4−TBX5 interaction, other heterotypic GATA4 protein
interactions require only a single binding element at the
promoter. Overall, previous studies suggest that NKX2-5 plays
both a structural15 and functional16 role as a dominant cofactor
of GATA4. Since an orchestrated and sequential expression of
transcription factors is essential for the development of cardiac
cells, theoretically, the inhibition of the GATA4−NKX2-5
protein complex would result in other GATA4-associated TF
combinations that would more efficiently program cells toward
a cardiomyocyte fate (Scheme 3). Interestingly, the increased
research efforts targeting nuclear receptors have revealed that
the interaction between GATA4 and NKX2-5 shares the same
architecture as the two zinc fingers in the DNA binding domain
of nuclear receptors,15 implicating that small molecules have
ability to modulate the GATA4 and NKX2-5 protein−protein
interactions.
In the present study, we identified four small molecule
families that produce either an agonistic or antagonist effect on
the GATA4−NKX2-5 transcriptional synergy. Here, we used
the NKE site to study the GATA4−NKX2-5 cooperative
interaction. The 3xNKE reporter is an artificial tool used to
detect the more pronounced signal from the GATA4−NKX2-5
synergy for screening purposes. Moreover, it has been shown
that the NKE site is essential for the GATA4−NKX2-5
cooperation in stretching-induced hypertrophy.14 A fragment-
based screening, transcriptional synergy measuring reporter
gene assay, and pharmacophore search were utilized for the
small molecule screening, identification, and optimization. The
primary screening using a reporter gene assay and the in vitro
cell culture studies revealed several biologically active
compounds, i.e., 3, 4, 5, 6, and 7, with distinct profiles. The
structure−activity relationship studies of inhibitory compounds
3, 4, and 5 demonstrated the indispensable role of the two
heavy atom linker together with a hydrogen acceptor feature
next to the five-member ring, while a completely opposite
agonistic effect was achieved by introducing a substituted five-
member ring into the amide bond (7). In the cardiomyocyte
cultures, the compounds either augmented or inhibited the
hypertrophic agonist-induced ANP and BNP expression. In
addition, the GPCR and kinase screenings with the most potent
compound, i.e., 3, N-[4-(diethylamino)phenyl]-5-methyl-3-
phenylisoxazole-4-carboxamide, did not detect cross-linking
pathways with the major cardiac signaling cascades. Compound
3 and its derivatives may provide a new class of small molecules
for modulating cardiogenesis and heart regeneration (Scheme
3). Even though the precise binding site of the tool compounds
in the GATA4−NKX2-5 interaction remains to be established,
the structural similarity and spatial appearance suggest the
existence of a common binding site that mediates the actions of
the active compounds. Of note, the results concerning
particular compounds may include unspecific effects, i.e., the
high concentration of compound 4 in the ET-1 assay, the
context-dependent degradation of the ester structure with
compound 5, and the frequent binder characteristic of
compound 6.48,49
Scheme 3. Transcriptional Activity of GATA4 Is Regulated by Interactions with Several Other TFs and Post-Translational
Modifications13,17−19,a
aMost of the protein−protein interactions of GATA factors are mediated by the C-terminal zinc finger, while the N-terminal zinc finger interacts
with Friend of GATA (FOG) transcription factors. Selected heterotypic interactions and DNA occupation modes for GATA4 are classified based on
experimental measurements of the binding preferences.25,42−46 Heterotypic GATA4 complex subpopulations have distinct context dependent effects
on the commitment of stem cells toward the cardiac fate or the enhancement of hypertrophic gene expression in mature cardiac cells. SRF, serum
response factor; SRE, serum response element; PTM, post-translational modification; Phos, phosphorylation; Acet, acetylation; Sumo/Ubi,
sumoylation/ubiquitination.
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Previously, numerous small molecule-based approaches have
been shown to enhance cardiac reprogramming, including the
activation of Wnt/β-catenin signaling (GSK3β inhibitors),
inhibition of Wnt-signaling (porcupine and tankyrase inhib-
itors), or modulation of transforming growth factor (TGF) β-
superfamily signaling (bone morphogenetic protein and TGFβ
inhibitors).50,51 These signaling pathways are essential during
the early phases of cardiac differentiation (mesoderm
induction).52 The combined application of Wnt- and TGFβ-
modulators requires strict time-dependent dosing in cellular
assays to yield optimal conditions for cardiac reprogramming.
Nevertheless, systematic protocol optimizations have led to a
powerful platform for cardiac differentiation from human
pluripotent stem cells using small molecule modulators of
Wnt-signaling.53 Additionally, very recently, Cao et al. and
Mohamed et al. presented pharmacological lineage-specific
approaches for the efficient conversion of human fibroblasts
into functional cardiomyocytes using either a combination of
nine small molecules54 or TGFβ- and Wnt-inhibitors jointly
with three cardiac transcription factors, i.e., GATA4, MEF2c,
and TBX5.55 However, the translation of the in vitro tool
compounds to in vivo candidates for cardiac regeneration is
challenging, e.g., requires the optimization of the physicochem-
ical or ADME properties that is necessary for efficacy in vivo.
Moreover, although the in vivo dosing of tool compounds that
regulate Wnt- or TGFβ-signaling may interfere with the
pathways beneficial for cardiac regeneration, these compounds
are potentially pro-oncogenic.50
Regarding the cardiac transcription factors, Sadek et al.
performed a small molecule library screening for chemical
activators of NKX2-5, which is one of the earliest lineage-
restricted genes to be expressed in cardiovascular progenitor
cells.56 A chemical library of 147 000 compounds was screened
in P19CL6 cells harboring an NKX2-5 luciferase reporter
construct, which led to the identification of 10 potential
molecular scaffolds with cardiogenic activity, including lead
compounds, such as sulfonylhydrazones (Shz-1) and isoxazoles
(Isx-9). Moreover, mechanistic follow-up studies suggest that
both Shz-1 (activation of Brachyury T together with early
cardiogenic program genes, such as NKX2-5 and myocardin56)
and Isx-9 (agonist of orphan GPR68, which is an extracellular
proton/pH sensing GPCR57) act independently of the known
procardiogenic pathways, such as Wnt and the TGFβ
superfamily. Of note, although various active molecular
scaffolds identified by Sadek et al. share similarities with the
compounds in the present study, including 3,5-disubstituted
isoxazoles vs 3,4,5-trisubstituted isoxazoles, thiazolidinediones,
and flavonoids, Isx-9 did not inhibit the luciferase reporter gene
activity in our GATA4−NKX2-5 transcriptional synergy assay
(data not shown).
In conclusion, adult cardiomyocytes are terminally differ-
entiated, and their capacity for renewal is limited in response to
cardiac injury.58 A core set of transcription factors control the
direct reprogramming of fibroblasts into induced cardiomyo-
cytes41,59−61 and directed differentiation of stem cells62,63 and
are, therefore, implicated as potential novel drug targets for
heart regeneration.39 One attractive strategy is to inhibit the
protein−protein interaction since many transcription factors act
as homo- or heterodimers and depend on cofactors to function
appropriately.36 Our results (3xNKE reporter assay, BNP
transcription, endothelin-1 stimulated gene expression of ANP
and BNP, hypertrophic cell surface growth in cardiomyocytes,
and immunoprecipitation assay) provide evidence of the small
molecule-mediated modulation of the transcriptional synergy
between GATA4 and NKX2-5, which plays essential roles in
programming cells toward the cardiomyocyte fate and
mediating the stretching-induced hypertrophic response.
GATA4 is also a critical regulator of biological processes in
myocardial remodeling and repair.13 However, the inhibitory
compounds could alter the interaction between GATA4 and
other binding partners, and thus a more detailed assessment
and validation of the molecular mechanism(s) and the
optimization of small molecules are needed to fully evaluate
the potential of GATA4−NKX2-5 interaction modulators in
chemically mediated cardiogenesis and heart repair and
regeneration.
■ EXPERIMENTAL SECTION
Homology Modeling and Sequence Alignment. A homology
model of GATA4 was constructed using the highly conserved C-
terminal zinc finger domain of GATA3 as a template structure
(Protein Data Bank code 3DFX, sequence identity 76%) for the C-
terminal zinc finger of GATA4. A homology model for the
homeodomain of NKX2-5 was built using the homeodomain of the
related thyroid transcription factor 1 as a template structure (Protein
Data Bank code 1FTT, sequence identity 61%). Other than the C- and
N-terminal domains, template structures are lacking and were,
therefore, excluded from the modeling. The sequence alignments
were constructed without any insertions or deletions using PSI-
BLAST. The commercial modeling package Molecular Operating
Environment (MOE 2014.09; Chemical Computing Group Inc.,
Montreal, Canada; www.chemcomp.com) was used to construct the
homology models of the protein domains. An AMBER99 force field
was applied as the source of the atom parameters for the protein
minimizations and scoring during the homology modeling. The side
chain data parameters were assembled from the extensive MOE-
integrated rotamer library. During the homology modeling, 10 protein
domain specific intermediate models were generated using the
Boltzmann-weighted randomized modeling procedure. All intermedi-
ate models were submitted to an electrostatic-enabled energy
minimization calculation until the root mean square (rms) gradient
fell below 1. Subsequently, the refined protein models were scored
using the generalized Born/volume integral (GB/VI) methodology.64
The highest scoring intermediate model was further minimized until
the rms fell below 0.5 and, subsequently, was selected as the final
model. The refined final models were inspected (bond lengths, bond
angles, atom clashes, and contact energies) and confirmed to have
satisfactory stereochemical quality using Ramachandran plots (φ and ψ
angles).65
In Silico Fragment Screening. Binding site assessments of the
homology models of GATA4 and NKX2-5 were carried out using the
MOE-integrated Alpha Site Finder calculation using the default
settings. Multiple copy simultaneous chemical probe analyses27 were
applied to the highest ranked binding pocket of the rigid GATA4
protein. MMFF94 was selected as the appropriate force field for the
receptor−ligand interactions. The DNA binding site of the GATA4
protein model was exposed to a collection of 39 randomly placed
molecular fragments and, subsequently, an energy minimization to
rank the interaction potential (with and without the solvent) of the
fragments with diverse functional groups inside the proposed binding
cavity. The default settings and protocols were applied to the fragment
library, number of fragment copies, energy minimization termination
gradient, and protein flexibility parameters.
Pharmacophore Preparation and Search. A flexible molecular
alignment was implemented to study the 3D molecular similarity to
elucidate the common pharmacophoric query of the three active
compounds (3, 4, and 5). The stochastic search procedure aligns the
conformational space of the molecules by maximizing the molecules’
chemical similarity with the least amount of internal strain. An
Amber12:EHT force field was applied for the molecule para-
metrizations and energy minimizations. Furthermore, the default
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settings were employed to score and rank the collection of compound
superpositions.66 The best-ranking alignment of active compounds was
utilized to generate the pharmacophore annotation points (four point
pharmacophore with two acceptor, aromatic, and hydrophobic
features). Excluded volume constraints derived from the GATA4
protein model were utilized as a shape restrictor in the pharmacophore
query. The MOE conformation database (650 000 leadlike compounds
from 44 chemical suppliers) was used as a ligand reservoir for the
pharmacophore search.
Screening of Commercial Small Molecules. Small molecules
for the primary screening and luciferase reporter gene assay based
optimization were selected and purchased from established suppliers,
including ChemBridge (San Diego, CA, USA), Enamine (Kiev,
Ukraine), Sigma-Aldrich (St. Louis, MO, USA), and Specs (Zoeter-
meer, The Netherlands). All compounds purchased for the study were
tested by HPLC−MS and 1H NMR by the vendors to confirm the
sample identity and ensure a minimum purity of 90%.
Chemistry. The synthesis of selected compounds (i.e., 3, 4, 7, 31,
and 32) were outsourced to Pharmatory (Oulu, Finland). All reactions
were carried out with commercially available solvents and chemicals.
All chemicals, solvents, and anhydrous solvents were acquired from
Sigma-Aldrich (Schnelldorf, Germany), Fluka (Buchs, Switzerland),
and Alfa Aesar (Ward Hill, MA, USA). The purity of the final
compounds was determined by HPLC/MS and 1H NMR (minimum
purity >95%). The 1H NMR spectra were observed at the University
of Oulu using a Bruker DPX 200 instrument (Rheinstetten, Germany)
in CDCl3 or DMSO-d6. The reported chemical shifts (δ) are expressed
in parts per million (ppm), and the coupling constants (J) are
expressed in hertz (Hz). The spin multiplicities are reported as s =
singlet, br s = broad singlet, d = doublet, t = triplet, q = quartet, m =
multiplet, and br = broad.
The HPLC−MS analysis was performed on an Agilent
Technologies 1100 HPLC fitted with Hewlett-Packard series 1100
MSD with Zorbax Extend-C18 150 mm × 4.6 mm, 5 μm, 30 °C, and
water + 0.20% v/v trifluoroacetic acid and acetonitrile as the eluent.
The HPLC analyses were performed on Zorbax Extend-C18 150 mm
× 4.6 mm, 5 μm at an ambient temperature using water + 0.20% v/v
trifluoroacetic acid and acetonitrile as the eluent.
General Synthetic Procedure for Manufacturing Compound
3 and Other Relative Compounds. One equivalent of a suitably
3,5-disubstituted isoxazole-4-carboxylic acid is dissolved in a solvent,
such as DMF, and the obtained solution is cooled to 0−10 °C. One
equivalent of a suitably substituted benzene-amine and an excess of O-
(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate
(TBTU) are added, and the mixture was stirred at 0−10 °C for 5−
30 min. An excess of a non-nucleophilic base, such as diisopropyl-
ethylamine, is slowly added, and the mixture is stirred at 0−10 °C for
2−5 h. Depending on the substituents used, either isoxazole-carboxylic
acid or benzene-amine, or both, can be modified by introducing
suitable protective groups to the selected substituents prior to their
reaction to yield the product compound.
An organic solvent of a suitable polarity, such as ethyl acetate and an
aq NaHCO3 solution, is added to the reaction mixture to dissolve the
compound, and the mixture is stirred at an ambient temperature until
dissolution occurs. The layers are separated, and the organic phase is
washed with water (e.g., 3 times) and brine (e.g., once). The organic
layer is then dried using a drying agent, such as sodium sulfate. The
drying agent is then filtered, and the solution is evaporated to dryness
to yield the crude compound.
The crude compound can be purified by dissolving it at a
temperature of 25−70 °C in a solvent of a suitable polarity, such as
ethyl acetate, and stirring the solution. An activated carbon can
optionally be added, and the mixture stirred and filtered through
Celite, whereby some impurities can be removed. Finally, precipitation
of the product can be achieved by cooling the solution to a point at
which it begins to crystallize or adding a second solvent with a polarity
opposite that of the first solvent, such as n-heptane, to the previous
solution and slowly cooling the mixture to a point at which the
product begins to crystallize. The pure precipitated product can then
be filtered, washed with the second solvent (e.g., twice), and dried,
optionally under vacuum.
N-[4-(Diethylamino)phenyl]-5-methyl-3-phenylisoxazole-4-
carboxamide (3). 5-Methyl-3-phenylisoxazole-4-carboxylic acid (8.00
g, 39.4 mmol) was dissolved in DMF (200 mL), and the solution
cooled to 0−10 °C. N′,N′-Diethylbenzene-1,4-diamine (6.47 g, 39.4
mmol) and TBTU (15.17 g, 47.3 mmol) were added, and the mixture
was stirred at 0−10 °C for 10 min. Diisopropylethylamine (6.11 g,
47.3 mmol) was slowly added, and the mixture was stirred at 0−10 °C
for 2.5 h. Ethyl acetate (400 mL) and a 5% aq NaHCO3 solution (160
mL) were added to the reaction mixture, and the mixture was stirred at
an ambient temperature for 15 min. The layers were separated, and the
organic phase was washed with water (3 × 200 mL) and brine (180
mL). The organic layer was dried with sodium sulfate, the drying agent
was filtered, and the solution evaporated to dryness to yield 12.8 g of
crude compound 3. The crude compound was dissolved in warm ethyl
acetate (300 mL), and activated carbon (0.5 g) was added. The
mixture was stirred for 20 min and filtered through Celite. n-Heptane
(120 mL) was added to the previous solution at 55 °C, and the
mixture was slowly cooled to 0−5 °C. The precipitated product was
filtered, washed with n-heptane (2 × 50 mL), and dried under vacuum
at 45 °C overnight to yield 8.52 g (62%) of compound 3 as an off-
white powder. NMR: 10.12 ppm (s, 1H, NH), 7.71 ppm (m, 2H,
arom), 7.35−7.50 ppm (m, 5H arom), 6.63 ppm (d, 2H, arom), 3.30
ppm (q, 4H, 2 × CH2), 2.55 ppm (s, 3H, CH3), 1.05 ppm (t, 6H, 2 ×
CH3). MS: m/z 350.2 (100%, M + 1), 351.2 (25%). Melting point
range: 139.3−140.2 °C.
4-[(4-Propoxybenzylidene)amino]-5-(pyridin-4-yl)-4H-1,2,4-
triazole-3-thiol (4). A mixture of 4-propoxybenzaldehyde (10.00 g,
60.9 mmol) and 4-amino-5-(pyridin-4-yl)-4H-1,2,4-triazole-3-thiol
(11.8 g, 60.9 mmol) in glacial acetic acid (100 mL) was heated to
reflux for 2.5 h, and the solution was filtered hot. The filtrate was
allowed to cool to an ambient temperature and was then cooled
further to 5 °C with an ice bath. The precipitated product was filtered,
washed with acetic acid (3 × 20 mL), and dried with suction to yield
17.8 g of crude compound 4. Crude compound 4 was dissolved in
boiling glacial acetic acid (110 mL), and the solution was allowed to
slowly cool to an ambient temperature. The precipitated product was
filtered, washed with acetic acid (2 × 10 mL) and water (2 × 10 mL),
and dried under vacuum at 40 °C for 8 h to yield 12.0 g (58%) of
compound 4. NMR (DMSO-d6): 9.51 ppm (s, 1H, SH), 8.75 ppm (m,
2H, arom), 7.88 ppm (m, 4H arom), 7.11 ppm (d, 2H, arom), 4.04
ppm (t, 2H, CH2), 1.76 ppm (m, 2H, CH2), 0.98 ppm (t, 3H, CH3).
MS: m/z 340.1 (100%, M + 1), 341.1 (22%), 362.0 (5%, M + Na).
Melting point: decomposition.
N-(4-Chlorophenyl)-5-methyl-N-(4-methyl-4,5-dihydrothia-
zol-2-yl)-3-phenylisoxazole-4-carboxamide (7). 5-Methyl-3-phe-
nylisoxazole-4-carboxylic acid (1.01 g, 4.97 mmol) was dissolved in
DMF (25 mL), and the solution was cooled to 0−10 °C. N-(4-
Chlorophenyl)-4-methyl-4,5-dihydrothiazol-2-amine (1.12 g, 4.94
mmol) and TBTU (1.90 g, 5.92 mmol) were added, and the mixture
was stirred at 0−10 °C for 10 min. Diisopropylethylamine (0.78 g,
6.04 mmol) was slowly added, and the mixture was stirred at 0−10 °C
for 4 h. The cooling bath was removed, and the mixture was stirred for
an additional 50 min, allowing it to warm to an ambient temperature.
Ethyl acetate (40 mL) and 10% aq NaHCO3 solution (35 mL) were
added to the reaction mixture, and the mixture was stirred at an
ambient temperature for 5 min. The layers were separated, and the
organic layer was washed with water (3 × 30 mL) and brine (15 mL).
The organic layer was dried with sodium sulfate, the drying agent was
filtered, and the solution was evaporated to dryness to yield 2.20 g of
crude compound 7. The crude material was dissolved in ethyl acetate
(10−12 mL) at an ambient temperature, and the solution was stirred
at an ambient temperature for 15 min; during this time, the product
began to crystallize out of the solution. n-Heptane (20 mL) was added,
and the mixture was stirred at an ambient temperature for 15 min;
during this period, more of the product precipitated. The precipitated
product was filtered, washed with n-heptane, and dried under vacuum
at 50 °C overnight to yield 1.53 g of compound 7 as a white powder.
NMR (CDCl3): 7.35−7.60 ppm (m, 5H, arom), 7.08−7.18 ppm (m,
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2H, arom), 6.31−6.43 ppm (m, 2H arom), 3.50−4.20 ppm (broad m,
2H thiazole CH2), 3.57 ppm (m, 1H, thiazole CH), 2.59 ppm (s, 3H,
CH3), 1.36 ppm (d, 3H, thiazole CH3). Melting point range: 145.6−
147.3 °C.
N-[4-(Ethylamino)phenyl]-5-methyl-3-phenylisoxazole-4-
carboxamide (31). 5-Methyl-3-phenylisoxazole-4-carboxylic acid
(300 mg, 1.48 mmol) was dissolved in DMF (7.5 mL), and the
solution was cooled to 0−10 °C. 1-N-Ethylbenzene-1,4-diamine (201
mg, 1.48 mmol) and TBTU (569 mg, 1.77 mmol) were added, and the
mixture was stirred at 0−10 °C for 10 min. Diisopropylethylamine
(0.30 mL, 1.77 mmol) was slowly added, and the mixture was stirred at
0−10 °C for 1.5 h. Ethyl acetate (30 mL) and 5% aq NaHCO3
solution (30 mL) were added to the reaction mixture, and the mixture
was stirred at an ambient temperature for 15 min. The layers were
separated, and the aqueous layer was washed with ethyl acetate (15
mL). The combined organic solutions were washed with water (30
mL) and brine (20 mL). The precipitated product was filtered and
dried under vacuum at 30 °C for 20 h to yield 282 mg of compound
31 as a pinkish powder. NMR (DMSO-d6): 10.05 ppm (s, 1H, NH),
7.71 ppm (m, 2H, arom), 7.50 ppm (m, 2H arom), 7.32 ppm (d, 2H
arom), 6.52 ppm (d, 2H, arom), 5.43 ppm (t, 1H, NH), 3.00 ppm (m,
2H, CH2), 2.55 ppm (s, 3H, CH3), 1.14 ppm (t, 3H, CH3). MS: m/z
322.1 (100%, M + 1), 344.2 (25%, M + Na). Melting point range:
203.1−205.9 °C.
N-[4-(Ethylamino)phenyl]-5-(hydroxymethyl)-3-phenylisox-
azole-4-carboxamide (32). Step 1. Magnesium ethoxide (4.85 g,
42.4 mmol) was suspended in dry toluene (9 mL), and ethyl benzoyl
acetate (7.40 g, 38.5 mmol) was added. After stirring the reaction
mixture for 1 h at room temperature, dry acetonitrile (9 mL) was
added, and the reaction mixture was cooled to −10 °C. Chloroacetyl
chloride (4.78 g, 3.37 mL, 42.4 mmol) was added for 35 min. The
reaction mixture was allowed to warm to room temperature and stirred
for 1 h. Sulfuric acid (1 mL) in ice−water (35 mL) was added to the
mixture, and the layers were separated. The aqueous layer was washed
with diethyl ether (20 mL), and the combined organic layers were
dried with magnesium sulfate. The drying agent was filtered, and the
filtrate was cooled to 0 °C. Triethylamine (5.4 mL) was dissolved in
diethyl ether (3 mL), and the mixture was added to the filtrate. The
reaction mixture was then stirred at room temperature for 40 min. The
precipitated triethylamine hydrochloride was filtered, and the solution
was evaporated to dryness to yield 9.74 g (109%) of crude ethyl 2-oxo-
4-phenyl-2,5-dihydrofuran-3-carboxylate (intermediate 1), which was
used in the next step without further purification.
Step 2. The crude intermediate 1, which was prepared as described
above (9.74 g), was dissolved in ethanol (39 mL), and hydroxylamine
hydrochloride (2.68 g, 38.5 mmol) and potassium acetate (3.78 g, 38.5
mmol) were added. The reaction mixture was heated to reflux for 40
min and then cooled to room temperature. Ethanol was removed by
evaporation under reduced pressure, and water (77 mL) was added to
the evaporation residue. The product was extracted with diethyl ether
(2 × 20 mL), and the combined organic layers were washed with brine
and dried with magnesium sulfate. The drying agent was filtered, and
the filtrate was evaporated to dryness under reduced pressure to yield
9.07 g (97% over two steps) of crude ethyl 5-(hydroxymethyl)-3-
phenylisoxazole-4-carboxylate (intermediate 2). NMR (CDCl3):
7.35−7.65 ppm (m, 5 H, arom), 4.95 ppm (s, 2H, CH2), 4.26 ppm
(q, 2 H, CH2), 1.20 ppm (t, 3H, CH3).
Step 3. Crude intermediate 2 (1.0 g, 4.04 mmol) was dissolved in
dichloromethane (28 mL) and 3,4-dihydro-2H-pyran (0.51 g, 6.07
mmol), and pyridinium p-toluenesulfonate (0.10 g, 0.4 mmol) was
added. The reaction mixture was stirred at room temperature for 6 h.
The reaction mixture was diluted with dichloromethane (20 mL) and
washed with half-diluted brine (40 mL). The organic layer was dried
with magnesium sulfate, the drying agent was filtered, and the filtrate
was evaporated to dryness to yield 1.38 (103%) of crude ethyl 3-
phenyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)isoxazole-4-carbox-
ylate (intermediate 3), which was used without further purification.
Step 4. The crude intermediate 3 (1.30 g, 3.92 mmol), which was
prepared as described above, was dissolved in methanol (39 mL), and
cesium carbonate (2.56 g, 7.85 mmol) was added. The reaction
mixture was stirred at an ambient temperature over the weekend. The
solution was evaporated to dryness under reduced pressure, and the
residue was divided between ethyl acetate (20 mL) and water (20
mL). The pH of the aqueous layer was adjusted to pH 2 with 37% aq
HCl, and the layers were separated. The aqueous layer was washed
with ethyl acetate (20 mL), the combined organic layers were dried
with magnesium sulfate, and the organic solution was evaporated to
dryness to yield 1.03 g (87%) of crude 3-phenyl-5-(((tetrahydro-2H-
pyran-2-yl)oxy)methyl)isoxazole-4-carboxylic acid (intermediate 4).
NMR (CDCl3): 8.19 ppm (broad s, 1H, COOH), 7.30−7.75 ppm (m,
5 H, arom), 5.09 ppm (q, 2H, CH2), 4.49 ppm (m, 1H, CH), 3.91
ppm (m, 1H, CH2), 3.61 ppm (m, 1H, CH2), 1.35−1.95 ppm (m, 6H,
CH2).
Step 5. Intermediate 4 (450 mg, 1.48 mmol) was dissolved in DMF
(12 mL), and the solution cooled to 0−10 °C. 1-N-Ethylbenzene-1,4-
diamine (220 mg, 1.62 mmol) and TBTU (577 mg, 1.80 mmol) were
added, and the mixture was stirred at 0−10 °C for 10 min.
Diisopropylethylamine (0.30 mL, 1.77 mmol) was slowly added, and
the mixture was stirred at 0−10 °C for 1.5 h. Ethyl acetate (40 mL)
and 5% aq NaHCO3 solution (30 mL) were added to the reaction
mixture, and the mixture was stirred at an ambient temperature for 15
min. The precipitated product was filtered, washed with ethyl acetate,
and dried to yield 560 mg (89%) of N-(4-(ethylamino)phenyl)-3-
phenyl-5-(((tetrahydro-2H-pyran-2-yl)oxy)methyl)isoxazole-4-carbox-
amide (intermediate 5), which was used in the final deprotection step.
NMR (DMSO-d6): 10.15 ppm (s, 1H, NH), 7.74 ppm (m, 2H, arom),
7.52 ppm (m, 3H arom), 7.32 ppm (d, 2H arom), 6.52 ppm (d, 2H,
arom), 5.44 ppm (t, 1H, NH), 4.82 ppm (q, 2H, CH2), 4.7 ppm (m,
1H, CH), 3.72 ppm (m, 1H, CH2), 3.45 ppm (m, 1H, CH2), 3.00 ppm
(q, 2H, CH2), 1.30−1.80 ppm (m, 6H, CH2), 1.00 ppm (t, 3H, CH3).
Compound 32. Intermediate 5 (70 mg, 0.17 mmol) was dissolved in
THF (1.4 mL), the pH of the solution was adjusted to pH 3 with 2 M
aq HCl solution, and the reaction mixture was stirred at an ambient
temperature overnight. The temperature of the solution was then
adjusted to 50 °C, and the stirring continued for 2 h. The pH was
adjusted to 9−10 with 5 M aq NaOH solution, and water (5 mL) was
added. The mixture was extracted with ethyl acetate (3 × 5 mL), and
the combined organic layers were washed with water (3 × 3 mL),
dried over sodium sulfate, and evaporated to dryness to yield 57 mg
(102%) of crude compound 32. The crude product was purified by
chromatography using ethyl acetate−heptane 1:1 as the eluent to yield
39 mg (71%) of compound 32. NMR (DMSO-d6): 10.07 ppm (s, 1H,
NH), 7.71 ppm (m, 2H, arom), 7.51 ppm (m, 3H arom), 7.31 ppm (d,
2H arom), 6.52 ppm (d, 2H, arom), 5.88 ppm (t, 1H, OH), 5.43 ppm
(t, 1H, NH), 4.71 ppm (d, 2H, CH2), 3.00 ppm (q, 2H, CH2), 1.14
ppm (t, 3H, CH3). MS: m/z 338.1 (100%, M + 1), 360.2 (25%, M +
Na).
Technique for the Detection of Aggregation. The compounds
of interest (i.e., compounds 3, 4, and 7) were diluted in DMSO to
obtain a stock of 100 mM, which was further diluted with DMSO to
obtain four different concentrations (100, 30, 10, and 3 mM). From
these concentrations 1 μL of solution was diluted to 1 mL of
Dulbecco’s modified Eagle’s medium (DMEM, Sigma-Aldrich/Gibco)
containing 10% fetal bovine serum (FBS, Gibco) and 1% penicillin−
streptomycin (PS, Sigma-Aldrich) (100 U/mL and 0.1 mg/mL,
respectively) referring the same conditions as in cell culture. Finally, an
amount of 100 μL of this solution was transferred to a 96-well
microplate (BRANDplates pureGrade). The final concentrations (i.e.,
100, 30, 10, and 3 μM) were in 0.1% DMSO. For the measurements,
DMEM with FBS and PS and 0.1% DMSO were used as a blank to
account for any signals due to the assay conditions. The blank and all
four concentrations of the samples were measured as triplicates at
three different voltages (300, 400, and 500 V) using a Nepheloskan
Ascent by Labsystems (Helsinki, Finland).
In Vitro Chemical Stability of Compound 3. HPLC−MS
CHROMASOLV grade chloroform, acetonitrile, formic acid, and
sodium chloride were obtained from Sigma (Darmstadt, Germany).
Water was freshly prepared in-house with a Milli-Q (Millipore Oy,
Espoo, Finland) purification system and was ultrapure grade (18.2
MΩ).
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Extraction Method for the Extracellular (Cell Culture Media)
Metabolites. Eight samples with no cells were thawed at room
temperature, and compound 3 was extracted from the cell culture
media with 500 μL of chloroform. The samples were vortexed briefly
and centrifuged at 16 000 rpm at 4 °C for 10 min. The bottom
chloroform layer was transferred to a glass vial and analyzed by
UPLC−ESI(+)-QTOF/MS in the sensitivity mode.
Extraction Method for the Intracellular Metabolites. Eight
samples with cell culture media and mouse embryonic stem cells were
thawed on ice and centrifuged at 16 000 rpm at 4 °C for 10 min. The
supernatants were removed, and cells were washed twice with 200 μL
of 0.9% saline (H2O), followed by centrifugation at 16 000 rpm at 4
°C for 10 min. The washed cells were disrupted, and compound 3 was
extracted with 200 μL of chloroform in an ultrasonic bath for 10 min,
followed by centrifugation at 16 000 rpm at 4 °C for 10 min. The
bottom chloroform phase was transferred to a glass vial and analyzed
by UPLC−ESI(+)-QTOF/MS in the sensitivity mode.
Analytical Method. A Waters Acquity ultraperformance liquid
chromatographic (UPLC) system (Waters Corp., Milford, MA, USA)
with an autosampler, vacuum degasser, and column oven was used.
The analytical column used was a Waters Acquity BEH C18 (2.1 mm
× 50 mm, 1.7 μm, Waters Corp, Milford, MA, USA), together with an
online filter. The used eluents were 0.1% formic acid in H2O (A) and
0.1% formic acid in acetonitrile (B). A linear gradient elution of 7%
B−80% B was applied for 5 min, followed by 1 min of column
equilibration. The flow rate was 0.6 mL/min, and the column oven
temperature was set to +40 °C. The LC−MS data were acquired using
a Waters Synapt G2 quadrupole-time-of-flight (QTOF) high definition
mass spectrometer (Waters Corp., Milford, MA, USA) equipped with
a LockSpray electrospray ionization source. A positive ionization mode
of electrospray was used with a cone voltage of 40 V and a mass range
of m/z 100−600. The mass spectrometer and UPLC system were
operated using MassLynx 4.1 software. Leucine enkephalin was used as
a lock mass compound ([M + H]+: 556.2771).
Plasmids. Rat BNP minimal promoter containing luciferase
reporter vector and minimal promoter together with −90 tandem
GATA-site have been described previously.9 The plasmid expressing
the mouse GATA4 (pMT2-GATA4) and the empty pMT2 plasmid
were gifts from D. B. Wilson (Department of Pediatrics, St. Louis
Children’s Hospital),67 and the plasmid expressing the mouse NKX2-5
(pEF-FLAG-NKX2-5) was provided by R. P. Harvey (the Victor
Chang Cardiac Research Institute, Darlinghurst, Australia).68 The
mouse NKX2-5 cDNA sequence was cloned from the pEF-plasmid to
the pMT2-plasmid as previously described.15 The p3xNKE-luc
plasmid was inserted into the pGL3 basic reporter vector containing
a rat albumin minimal promoter with a TATA-box (−40 to +28),
which was a kind gift from J. Hakkola (Department of Pharmacology
and Toxicology, University of Oulu, Finland)69 as previously
described.15 The internal control vector pRL-TKd238 was a gift
from J. F. Strauss III (University of Pennsylvania School of Medicine,
Philadelphia).70
In Vitro Screening. In total, 800 small molecules were analyzed in
vitro using an immunoprecipitation assay or a luciferase reporter gene
assay specifically developed for the GATA4−NKX2-5 transcriptional
synergy. For the luciferase reporter assay, mammalian COS-1 cells
were cultured on 48-well plates (Greiner Bio One) in Dulbecco’s
modified Eagle’s medium (Sigma-Aldrich/Gibco) containing 10% fetal
bovine serum (Gibco) and 1% penicillin−streptomycin (Sigma-
Aldrich) (100 U/mL and 0.1 mg/mL, respectively). In addition to
co-transfecting all wells with the firefly luciferase reporter vector
p3xNKE-luc and the internal control Renilla luciferase vector pRL-
TKd238, one set of cells was transfected with the protein expression
vector pMT2-GATA4, one set of cells was transfected with pMT2-
NKX2-5, one set of cells was transfected with both pMT2-GATA4 and
pMT2-NKX2-5, and the final set of cells was transfected with the
empty control vector pMT2. For the transfections, the ratio of DNA/
transfection reagent (Fugene 6, Roche Applied Science) was 1:3. The
total plasmid DNA concentration was normalized across all wells by
adding the empty vector pMT2. The compounds were added to the
cells 6 h after the transfections, and each well contained 0.1% DMSO.
The medium containing the compounds was changed to a fresh one
24 h after the transfection. Thirty hours after the transfection, the cells
were lysed with 1× passive lysis buffer (E194A, Promega). The
samples were processed on a dual-luciferase assay system (E1960,
Promega) according to manufacturer’s protocol and measured with a
luminometer (Luminoskan RS, Labsystems, Helsinki, Finland). Each
compound was tested in two parallel samples. For the analysis of the
results, the Firefly values were divided by the Renilla values and then
normalized to the vehicle-treated control values.
COS-1 Cell Culture. COS-1 cells were cultured as previously
described.15 For the nuclear protein extractions, the cells were plated
in 25 cm2 cell culture bottles 24 h before the transfection. The pMT2-
GATA4 or pMT2-NKX2-5 plasmids were transfected as described
above. After 48 h, the transfected cells were collected.
BNP Reporter Assay. COS-1 cells were cultured on 48-well plates
(Greiner Bio One) in Dulbecco’s modified Eagle’s medium (Sigma-
Aldrich/Gibco) containing 10% fetal bovine serum (Gibco) and 1%
penicillin−streptomycin (Sigma-Aldrich) (100 U/mL and 0.1 mg/mL,
respectively). In addition to co-transfecting all wells with the firefly
luciferase reporter vector containing either BNP minimal promoter or
−90 bp BNP promoter and the internal control Renilla luciferase
vector pRL-TKd238, one set of cells was transfected with the protein
expression vector pMT2-GATA4 and another set of cells was
transfected with the empty vector pMT2. The compounds were
added to the cells 6 h after the transfections; each well contained 0.1%
DMSO. The medium was changed to a fresh one 24 h after the
transfection, and also fresh compounds were added to the cells. Thirty
hours after the transfection, the cells were lysed with 1× passive lysis
buffer (E194A, Promega). The samples were processed on a dual-
luciferase assay system (E1960, Promega) according to the
manufacturer’s protocol and measured with a luminometer (Lumi-
noskan RS, Labsystems, Helsinki, Finland). Each compound was
tested in three parallel samples. For the analysis of the results, the
firefly values were divided by the Renilla values and then normalized to
the vehicle-treated control values.
Neonatal Cardiomyocyte Culture. The cell culture reagents
were obtained from Sigma-Aldrich unless otherwise stated. Primary
cultures of neonatal rat ventricular cardiomyocytes were prepared from
2- to 4-day-old Sprague-Dawley or Wistar rats.14 The animals were
sacrificed by decapitation, and the ventricles were excised and cut into
small pieces. The ventricle pieces were incubated at 37 °C by shaking
for 2 h in a solution containing 100 mM NaCl, 10 mM KCl, 1.2 mM
KH2PO4, 4.0 mM MgSO4, 50 mM taurine, 20 mM glucose, 10 mM
Hepes, 2 mg/mL collagenase type 2 (Worthington, Lakewood), 2 mg/
mL pancreatin, and 1% PS (Gibco). After the incubation, the cell
suspension was collected into 15 mL tubes and centrifuged for 5 min
at 160g. The supernatant and the top layer of the pellet containing the
damaged cells were discarded, and the isolated cardiomyocytes were
suspended in Dulbecco’s modified Eagle medium (DMEM)/F12
culture medium containing 2.5 mM L-glutamine, supplemented with
1% PS and 10% fetal bovine serum (Gibco). The cells were preplated
for 30−90 min on cell culture plates with a 10 cm diameter, and the
unattached cardiomyocytes were collected with the medium. The
number of viable cells was determined, and the cells were seeded onto
six-well plates (Corning) at a density of (1.5−2) × 105 cells/well
according to the assay used. The following day, the medium was
replaced with complete serum free medium (CSFM; DMEM/F12, 2.5
mg/mL bovine serum albumin, 1 μM insulin, 2.5 mM L-glutamine, 32
nM selenium, 2.8 mM sodium pyruvate, 5.64 μg/mL transferrin, 1 nM
T3, and 100 IU/mL PS). The cells were cultured for another 24 h
before adding the compounds. For the DNA binding assay, the cells
were treated for 24 h with the compounds at a concentration of 50
μM. For the analysis of the hypertrophic gene expression, the cells
were treated with 100 nM endothelin 1 (ET-1, Sigma-Aldrich) for 24
h, and compounds were added to the cells 1 h prior to addition of ET-
1. The temperature in the culture chamber was 37 °C with 5% CO2
and 95% air atmosphere.
Nuclear Protein Extraction. After the appropriate treatments, the
cultured cells were washed, and the protein extracts were prepared as
previously described.14,71
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Coimmunoprecipitation Assay. GATA4 and NKX2-5 FLAG
proteins as well the cell lysate without transfection were produced in
COS-1 cells. Agarose bound anti-FLAG M2 antibody (Sigma) was
incubated with proteins in lysis buffer (20 mM Tris, 150 mM NaCl, 1
mM EDTA, 1 mM EGTA, 1% Triton X-100, 2.5 mM sodium
pyrophosphate) supplemented with protease and phosphatase
inhibitors (200 μM sodium orthovanadate, 20 μg/mL leupeptin, 2
μg/mL pepstatin, 20 μg/mL aprotinin, 1 mM phenylmethanesulfonyl
fluoride, 50 mM sodium fluoride, 6 μg/mL N-tosyl-L-phenylalaninyl-
chloromethyl ketone, 6 μg/mL N-α-tosyl-L-lysinyl-chloromethyl
ketone) overnight at +4 °C with gentle end-over-end mixing. The
beads were collected by quick spin with a table top microcentrifuge
and washed three times with lysis buffer. The immunoprecipitated
proteins were eluted from the agarose beads by boiling the samples in
SDS-loading buffer, resolved by SDS−PAGE, transferred onto
Optitran BA-S 85 reinforced nitrocellulose membrane (Schleicher &
Schuell) and immunoblotted with anti-GATA4 polyclonal antibody
(sc-9053, Santa Cruz Biotechnology) and anti-NKX2-5 polyclonal
antibody (sc-8697, Santa Cruz Biotechnology). Horseradish perox-
idase conjugated anti-rabbit IgG or anti-goat IgG was used as
secondary antibody. The immune complex was visualized by using an
ECL detection kit (Amersham Pharmacia Biotech) followed by
exposure to film (Hyperfilm ECL, Amersham Biosciences) or
digitalization of chemiluminescence with luminescent imager analyzer
LAS-3000 (Fujifilm). All results were quantitated by using Quantitiy
One software (Bio-Rad).
Isolation and Analysis of RNA. Total RNA from the cultured
cardiomyocytes was isolated with TRIzol reagent (Invitrogen)
following the manufacturer’s protocol using the phase lock gel system
(Eppendorf AG). For the quantitative real-time polymerase chain
reaction (RT-PCR) analyses, cDNA was synthesized from the total
RNA using a first-strand cDNA synthesis kit (GE Healthcare Life
Sciences) following the manufacturer’s protocol. The RNA was
analyzed by RT-PCR on an ABI 7300 sequence detection system
(Applied Biosystems) using TaqMan chemistry. The sequences of the
forward and reverse primers and fluorogenic probes for the RNA
detection are shown in Table 5. The results were normalized to 18S
RNA quantified from the same samples.
Mechanical Stretching of Cardiomyocytes. After the cell
isolation, the neonatal rat ventricular cardiomyocytes were seeded at a
density of 106 cells/well on collagen I coated flexible-bottomed six-well
plates (BioFlex collagen I, Flexcell International Corp., Burlington,
NC) and cultured for 48 h before the treatments. The cardiomyocytes
were exposed to the compounds or vehicle in CSFM and subjected to
equibiaxial cyclic mechanical stretching (0.5 Hz, 10−20% elongation)
for 48 h using a FlexCell tension system FX-5000 (Flexcell
International Corp., Burlington, NC). Nonstretched cardiomyocytes
seeded on similar BioFlex plates served as controls.
Immunofluorescence Staining. To investigate the effect of the
stretching on the cardiomyocyte size, the cells were washed twice with
PBS and fixed with 4% paraformaldehyde for 20 min at room
temperature (rt) immediately after the 48 h stretching. The cells were
then washed with 0.2% bovine serum albumin in Dulbecco’s PBS
(DB) and permeabilized with 0.1% Triton X-100 in PBS for 10 min at
rt, followed by two 10 min washes in DB. Square pieces (10−15 mm ×
10−15 mm) of the silicone membranes were then cut from the centers
of the wells, incubated with a primary antibody against sarcomeric α-
actinin (at 1:800 in DB, Sigma-Aldrich A7811) for 60 min at rt,
washed three times for 10 min with DB, and incubated with the Alexa
Fluor 488 anti-mouse secondary antibody (at 1:200 in DB, Life
Technologies A-11029) and Alexa Fluor 647 phalloidin (at 1:140 in
DB, Life Technologies A22287) for 45 min at rt. After three 10 min
washes with DB, the specimens were mounted on microscopy slides
using ProLong Gold Antifade Mountant with DAPI (Molecular
Probes) and cured overnight at RT, after which they were stored at 4−
8 °C.
Analysis of the Cell Surface Area. For the cell surface area
analysis, a minimum of six images of each stretched or nonstretched
specimen were captured with a Hamamatsu Orca-Flash4.0 V2 camera
(Hamamatsu Photonics, Hamamatsu, Japan) attached to a Leica
DM6000B fluorescence microscope using 20×/0.7 HC PL APO CS2
objective and Leica Application Suite X software (Leica Microsystems,
Wetzlar, Germany). The cell surface areas of the cardiomyocytes were
determined from the images using CellProfiler software.72,73 In brief,
the nuclei were identified based on DAPI staining, followed by the
detection of cell edges using an overlay of the fluorescence images of
α-actinin and phalloidin. The cells were then filtered based on the α-
actinin staining, and the surface areas of the α-actinin+ cells
(cardiomyocytes) were determined. The mean cell surface areas
were calculated for each specimen (>200 cells/specimen) and
normalized to the mean cell surface area of the untreated,
nonstretched cardiomyocytes from the same experiment.
DNA Binding Properties. The effect of the compounds on the
DNA binding abilities of GATA4 and NKX2-5 was studied by
performing an electrophoretic mobility shift assay (EMSA). The
GATA4 or NKX2-5 proteins used in the binding reactions were
overexpressed proteins from the COS-1 cells or endogenous proteins
from neonatal rat cardiomyocytes treated with the compounds for 24 h
before the nuclear protein extraction. The nuclear protein extracts
from the cells were incubated with a radioactively labeled double
stranded oligonucleotide, which contained either the GATA4 or
NKX2-5 specific binding site. For GATA4, the double-stranded
oligonucleotide corresponded to the GATA binding region −90, i.e.,
Δ−68/−97 of the rat BNP promoter (GenBank code M60266) as
follows: rBNP −90 tandem GATA (5′-TGTGTCTGATAAAT-
CAGAGATAACCCCACC-3′). For NKX2-5, the double-stranded
oligonucleotide corresponded to the NKX2-5 binding element in the
ANP promoter region (GenBank code M27498) as follows: rANP
−240 NKE-like element (5′-AGAGACCTTTGAAGTGGGGGCC-
TCTTGAGGCCCCG-3′). The probes were sticky-end-labeled with
[α-32P]dCTP by Klenow enzyme. For each binding reaction mixture,
the nuclear/total GATA4 or NKX2-5 protein was used in a final
concentration of 16 mM HEPES, 120 mM NaCl, 0.67 mM EDTA, 0.3
mM EGTA, 8% glycerol, 0.02% NP-40, 40 mM KCl, 1 mM MgCl2, 0.1
μg/μL poly(dIxdC)2, 0.5 mM Tris-HCl (pH 7.5), 1 mM PMSF, 40
μg/mL aprotinin, 40 μg/mL leupeptin, and 4 μg/mL pepstatin. The
final volume of the binding reaction was equalized to 20 μL with a high
salt buffer. Reaction mixtures containing the nuclear proteins from the
COS-1 cells were incubated with the compounds for 10 min before
adding the labeled probes. After 20 min of incubating the nuclear
protein with the probe, the protein−DNA mixtures were separated by
nondenaturating gel electrophoresis on 5% polyacrylamide gel. For the
supershift assay, either the GATA4 antibody (sc-1237X, Santa Cruz
Biotechnology) or NKX2-5 antibody (sc-8697X, Santa Cruz
Biotechnology) was incubated for 10 min with the protein sample
before adding the compounds. Subsequently, the gels were dried and
exposed to PhosphorImager screens (Molecular Dynamics, Sunnyvale,
CA, USA). The screens were scanned using a Bio-Rad molecular
imager FX Pro Plus and analyzed with Quantity One software (Bio-
Rad Laboratories).
In Vitro Cytotoxicity. The release of adenylate kinase (AK) from
the ruptured rat cardiac cells into the cell culture medium was analyzed
Table 5. Forward and Reverse Primers and Fluorogenic
Probe Sequences Used for the Quantitative RT-PCR
Analysis
gene sequence
ANP forward GAAAAGCAAACTGAGGGCTCTG
reverse CCTACCCCCGAAGCAGCT
fluorogenic probe TCGCTGGCCCTCGGAGCCT
BNP forward TGGGCAGAAGATAGACCGGA
reverse ACAACCTCAGCCCGTCACAG
fluorogenic probe CGGCGCAGTCAGTCGCTTGG
18S forward TGGTTGCAAAGCTGAAACTTAAAG
reverse AGTCAAATTAAGCCGCAGGC
fluorogenic probe CCTGGTGGTGCCCTTCCGTCA
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using a ToxiLight bioassay kit (nondestructive cytotoxicity assay) from
Lonza Rockland Inc. (Rockland, ME, USA) according to the
manufacturer’s instructions. A luminometer (Luminoskan RS,
Labsystems, Helsinki, Finland) was used to measure the bio-
luminescence of AK in the medium after 24 h of treatment with the
compounds at a concentration of 50 μM. To detect the apoptotic
myocytes, a terminal deoxynucleotidyl transferase-mediated dUTP
nick end-labeling (TUNEL) assay was performed. The rat cardiac
myocytes were plated onto Nunc Lab-Tek chamber slide system eight-
well slides (Thermo Fisher Scientific Inc.). The cells were treated with
the compounds at a concentration of 50 μM for 24 h. The apoptotic
cells were detected using the ApopTag peroxidase in situ apoptosis
detection kit (Millipore).
In Vitro Kinase Profiling. The effect of the compounds 3 and 4
on the activity of 48 kinases was assessed by Cerep’s ExpresS Diversity
kinase profile service (Cerep, France). The compounds were tested at
a concentration 30 μM in duplicate.
GPCR Profiling. The effect of the compound 3 in terms of GPCR
agonism and antagonism was tested by GPCRProfiler (Millipore,
Germany), which comprises cell-based functional assays for 165
GPCRs. The compound was used to test agonistic activities at a
concentration of 12.5 μM and antagonistic activities at a concentration
of 10 μM in duplicate.
Statistics. The results are expressed as the mean ± standard
deviation (SD). The statistical analyses were performed using SPSS
version 22 (SPSS Inc., Chicago, IL, USA). To determine the significant
difference between two groups, independent samples of Student’s t-
tests were used. For multiple comparisons, the statistical significance
was evaluated by one-way analysis of variance (ANOVA), followed by
Bonferroni post hoc tests. The probability values of (∗) p < 0.05, (∗∗)
p < 0.01, and (∗∗∗) p < 0.001 were considered statistically significant.
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